These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

544 related articles for article (PubMed ID: 26378211)

  • 61. Use of direct oral anticoagulants for stroke prevention in elderly patients with nonvalvular atrial fibrillation.
    Oertel LB; Fogerty AE
    J Am Assoc Nurse Pract; 2017 Sep; 29(9):551-561. PubMed ID: 28805310
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Apixaban: a new factor Xa inhibitor for stroke prevention in patients with nonvalvular atrial fibrillation.
    Lam S
    Cardiol Rev; 2013; 21(4):207-12. PubMed ID: 23535530
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Design and Rationale of the RELAXED (Recurrent Embolism Lessened by rivaroxaban, an Anti-Xa agent, of Early Dosing for acute ischemic stroke and transient ischemic attack with atrial fibrillation) Study.
    Yasaka M; Minematsu K; Toyoda K; Yamagami H; Yoshimura S; Nagao T; Mori E; Hirano T; Hamasaki T; Yamaguchi T
    J Stroke Cerebrovasc Dis; 2016 Jun; 25(6):1342-8. PubMed ID: 26987488
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Edoxaban, a Novel Oral Factor Xa Inhibitor.
    Minor C; Tellor KB; Armbruster AL
    Ann Pharmacother; 2015 Jul; 49(7):843-50. PubMed ID: 25855704
    [TBL] [Abstract][Full Text] [Related]  

  • 65. The Role of Nonvitamin K Antagonist Oral Anticoagulants (NOACs) in Stroke Prevention in Patients with Atrial Fibrillation.
    Kuznetsov S; Barcelona R; Josephson RA; Mohan SK
    Curr Neurol Neurosci Rep; 2016 May; 16(5):47. PubMed ID: 27023335
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Anti-Xa activity in oral factor Xa inhibitor-treated patients with atrial fibrillation and a higher risk of bleeding: a pilot study.
    Samoš M; Bolek T; Stančiaková L; Škorňová I; Bánovčin P; Kovář F; Staško J; Galajda P; Kubisz P; Mokáň M
    Blood Coagul Fibrinolysis; 2018 Jun; 29(4):369-373. PubMed ID: 29538002
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Noncentral Nervous System Systemic Embolism in Patients With Atrial Fibrillation: Results From ROCKET AF (Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).
    Orgel R; Wojdyla D; Huberman D; Halperin JL; Breithardt G; Singer DE; Fox KAA; Hankey GJ; Mahaffey KW; Jones WS; Patel MR
    Circ Cardiovasc Qual Outcomes; 2017 May; 10(5):. PubMed ID: 28495674
    [No Abstract]   [Full Text] [Related]  

  • 68. Factor Xa Inhibitors Versus Vitamin K Antagonists in Atrial Fibrillation Patients with End-Stage Kidney Disease on Dialysis: A Meta-Analysis.
    Xiong M; Guo L; Wan Y
    Clin Appl Thromb Hemost; 2024; 30():10760296241271423. PubMed ID: 39140874
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Edoxaban in patients with atrial fibrillation.
    Eisen A; Ruff CT
    Ther Adv Cardiovasc Dis; 2017 Mar; 11(3):81-90. PubMed ID: 26680560
    [TBL] [Abstract][Full Text] [Related]  

  • 70. The problem of underdosing with direct-acting oral anticoagulants in elderly patients with nonvalvular atrial fibrillation.
    Fernández CS; Gullón A; Formiga F
    J Comp Eff Res; 2020 May; 9(7):509-523. PubMed ID: 32329353
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Direct Oral Anticoagulants for the Prevention of Stroke in Patients with Nonvalvular Atrial Fibrillation: Understanding Differences and Similarities.
    Dobesh PP; Fanikos J
    Drugs; 2015 Sep; 75(14):1627-44. PubMed ID: 26370208
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Clinical utility of rivaroxaban in stroke prevention associated with nonvalvular atrial fibrillation - patient considerations.
    Ahrens I; Bode C
    J Blood Med; 2014; 5():25-30. PubMed ID: 24591854
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Renal Function in Atrial Fibrillation: A Multifaceted Dilemma.
    Hijazi Z; Wallentin L
    Circulation; 2016 Jul; 134(1):48-51. PubMed ID: 27358436
    [No Abstract]   [Full Text] [Related]  

  • 74. [Rivaroxaban use in prevention of stroke in patients with non-valvular atrial fibrillation in clinical practice, results of observational studies and our experience].
    Málek F
    Vnitr Lek; 2016; 62(10):814-819. PubMed ID: 27900868
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Therapeutic Plasma Exchange for Urgent Rivaroxaban Reversal.
    Kumar V; Allencherril J; Bracey A; Chen AJ; Lam WW
    Tex Heart Inst J; 2018 Apr; 45(2):96-98. PubMed ID: 29844742
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Factor Xa inhibitors vs warfarin for preventing stroke and thromboembolism in patients with atrial fibrillation.
    Bruins Slot KM; Berge E
    JAMA; 2014 Mar; 311(11):1150-1. PubMed ID: 24643605
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Factor Xa inhibitors differently modulate electrical activities in pulmonary veins and the sinoatrial node.
    Chang CJ; Cheng CC; Chen YC; Higa S; Huang JH; Chen SA; Chen YJ
    Eur J Pharmacol; 2018 Aug; 833():462-471. PubMed ID: 30017860
    [TBL] [Abstract][Full Text] [Related]  

  • 78. [Anticoagulation. Modern concepts].
    Perrey M; Erbel R
    Herz; 2012 Jun; 37(4):407-13; quiz 414-5. PubMed ID: 22592953
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Incremental economic burden associated with major bleeding among atrial fibrillation patients treated with factor Xa inhibitors.
    Deitelzweig S; Neuman WR; Lingohr-Smith M; Menges B; Lin J
    J Med Econ; 2017 Dec; 20(12):1217-1223. PubMed ID: 28760063
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Review of atrial fibrillation outcome trials of oral anticoagulant and antiplatelet agents.
    Bassand JP
    Europace; 2012 Mar; 14(3):312-24. PubMed ID: 22355190
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.